Jonathan Fintzi

Jonathan Fintzi

Auto-generated profile, based on publicly available information

Jonathan Fintzi

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases , Rockville, Maryland , USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MAMichael S. Abers
Michael S. Abers
ODOttavia M. Delmonte
Ottavia M. Delmonte
EREmily E. Ricotta
Emily E. Ricotta
JFJonathan Fintzi
Jonathan Fintzi
DFDanielle L. Fink
Danielle L. Fink
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN–, type II IFN–, and NF-κB–dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients’ first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.

17 September 2021 in Science
Verified
Journal Article
Open access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
MNMartha C. Nason
Martha C. Nason
BFBritta Flach
Britta Flach
MGMatthew Gagne
Matthew Gagne
SOSarah O’connell
Sarah O’connell
RSRobert Seder
Robert Seder
Antibodies dovetail with protection: Immune correlates of protection are clinical end points used to gauge vaccine-induced immunogenicity and protection. Corbett et al . studied nonhuman primate (NHP) immune responses to various doses of the mRNA-1273 (Moderna) vaccine to provide a range of immune responses and protective outcomes. They determined that circulating spike protein–specific antibodies correlated with protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in the airways. Passively transferred NHP antibodies were sufficient to mediate protection against SARS-CoV-2 challenge in hamsters, emphasizing that antibodies are mechanistic correlates. Protection of the lower respiratory tract required lower serum antibody concentrations, possibly explaining why most current vaccines are highly effective against severe lower airway disease. The higher antibody threshold required for reducing upper airway infection has potential implications for boosting to limit transmission. —STS

9 August 2021 in Biometrics
Verified
Journal Article
Closed access
PDF file
JFJonathan Fintzi
Jonathan Fintzi
JWJon Wakefield
Jon Wakefield
VMVladimir N. Minin
Vladimir N. Minin

29 April 2021 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
JFJonathan Fintzi
Jonathan Fintzi
DFDean Follmann
Dean Follmann
Randomized vaccine trials are used to assess vaccine efficacy (VE) and to characterize the durability of vaccine‐induced protection. If efficacy is demonstrated, the treatment of placebo volunteers becomes an issue. For COVID‐19 vaccine trials, there is broad consensus that placebo volunteers should be offered a vaccine once efficacy has been established. This will likely lead to most placebo volunteers crossing over to the vaccine arm, thus complicating the assessment of long term durability. We show how to analyze durability following placebo crossover and demonstrate that the VE profile that would be observed in a placebo controlled trial is recoverable in a trial with placebo crossover. This result holds no matter when the crossover occurs and with no assumptions about the form of the efficacy profile. We only require that the VE profile applies to the newly vaccinated irrespective of the timing of vaccination. We develop different methods to estimate efficacy within the context of a proportional hazards regression model and explore via simulation the implications of placebo crossover for estimation of VE under different efficacy dynamics and study designs. We apply our methods to simulated COVID‐19 vaccine trials with durable and waning VE and a total follow‐up of 2 years.

19 March 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
Carrie Mae LongCarrie Mae Long
Carrie Mae Long
PBPaul A. Beare
Paul A. Beare
DCDiane C. Cockrell
Diane C. Cockrell
JFJonathan Fintzi
Jonathan Fintzi
MTMahelat Tesfamariam
Mahelat Tesfamariam
RHRobert Heinzen
Robert Heinzen
Coxiella burnetiiis the bacterial causative agent of the zoonosis Q fever. The current human Q fever vaccine, Q-VAX®, is a fixed, whole cell vaccine (WCV) licensed solely for use in Australia.C. burnetiiWCV administration is associated with a dermal hypersensitivity reaction in people with pre-existing immunity toC. burnetii, limiting wider use. Consequently, a less reactogenic vaccine is needed. Here, we investigated contributions of theC. burnetiiDot/Icm type IVB secretion system (T4BSS) and lipopolysaccharide (LPS) in protection and reactogenicity of fixed WCVs. A 32.5 kb region containing 23dot/icmgenes was deleted in the virulent Nine Mile phase I (NMI) strain and the resulting mutant was evaluated in guinea pig models ofC. burnetiiinfection, vaccination-challenge, and post-vaccination hypersensitivity. The NMI ∆dot/icmstrain was avirulent, protective as a WCV against a robustC. burnetiichallenge, and displayed potentially altered reactogenicity compared to NMI. Nine Mile phase II (NMII) strains ofC. burnetiithat produce rough LPS, were similarly tested. NMI was significantly more protective than NMII as a WCV; however, both vaccines exhibited similar reactogenicity. Collectively, our results indicate that, like phase I LPS, the T4BSS is required for full virulence byC. burnetii. Conversely, unlike phase I LPS, the T4BSS is not required for vaccine-induced protection. LPS length does not appear to contribute to reactogenicity while the T4BSS may contribute to this response. NMI ∆dot/icmrepresents an avirulent phase I strain with full vaccine efficacy, illustrating the potential of genetically modifiedC. burnetiias improved WCVs.

1 August 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
DFDean Follmann
Dean Follmann
JFJonathan Fintzi
Jonathan Fintzi
MFMichael P. Fay
Michael P. Fay
HJHolly E. Janes
Holly E. Janes
LBLindsey R. Baden
Lindsey R. Baden
KNKathleen M. Neuzil
Kathleen M. Neuzil
Continued follow-up of participants in COVID-19 vaccine trials after vaccination of the placebo group permits determination of vaccine durability and allows the incorporation of a booster trial if ... Multiple candidate vaccines to prevent COVID-19 have entered large-scale phase 3 placebo-controlled randomized clinical trials, and several have demonstrated substantial short-term efficacy. At som...